CLAUDIA published in Archivos de Bronconeumología

Tumor Marker Innovation is pleased to announce the publication of a new scientific article in Archivos de Bronconeumología: “Clinical Application of Expert Software Based on Six Tumour Biomarkers to Stratify the Risk of Lung Cancer in a Pulmonary Rapid Diagnosis Unit.”

The study evaluates the clinical application of expert software based on six tumour biomarkers — CEA, CYFRA 21.1, CA 15-3, SCC Ag, ProGRP and NSE — combined with clinical and imaging data to estimate lung cancer risk.

In a multicentre study including 2,005 patients from 12 reference hospitals in Spain and Portugal, the software achieved 87.7% sensitivity, 75.5% specificity, 89.0% positive predictive value and 73.0% negative predictive value. The publication highlights that the software can help stratify lung cancer risk and support clinical decision-making, particularly in Pulmonary Rapid Diagnosis Units.

This publication reinforces the role of CLAUDIA as a clinical decision-support tool designed to help healthcare professionals prioritize patients at higher risk and optimize diagnostic procedures.

Read the full publication:
Clinical Application of Expert Software Based on Six Tumour Biomarkers to Stratify the Risk of Lung Cancer in a Pulmonary Rapid Diagnosis Unit
Archivos de Bronconeumología, available online January 9, 2026.